<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>TET2 is a close relative of TET1, an enzyme that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA </plain></SENT>
<SENT sid="1" pm="."><plain>The gene encoding TET2 resides at chromosome 4q24, in a region showing recurrent microdeletions and copy-neutral loss of heterozygosity (CN-LOH) in patients with diverse <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Somatic TET2 mutations are frequently observed in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN <z:e sem="disease" ids="C0410000" disease_type="Disease or Syndrome" abbrv="">overlap syndromes</z:e> including <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> (sAML) </plain></SENT>
<SENT sid="3" pm="."><plain>We show here that TET2 mutations associated with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> compromise catalytic activity </plain></SENT>
<SENT sid="4" pm="."><plain>Bone marrow samples from patients with TET2 mutations displayed uniformly low levels of 5hmC in genomic DNA compared to bone marrow samples from healthy controls </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, small hairpin <z:chebi fb="40" ids="33697">RNA</z:chebi> (shRNA)-mediated <z:mpath ids='MPATH_63'>depletion</z:mpath> of Tet2 in mouse haematopoietic precursors skewed their differentiation towards monocyte/macrophage lineages in culture </plain></SENT>
<SENT sid="6" pm="."><plain>There was no significant difference in DNA methylation between bone marrow samples from patients with high 5hmC versus healthy controls, but samples from patients with low 5hmC showed hypomethylation relative to controls at the majority of differentially methylated CpG sites </plain></SENT>
<SENT sid="7" pm="."><plain>Our results demonstrate that Tet2 is important for <z:mpath ids='MPATH_458'>normal</z:mpath> myelopoiesis, and suggest that disruption of TET2 enzymatic activity favours myeloid <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Measurement of 5hmC levels in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> may prove valuable as a diagnostic and prognostic tool, to tailor therapies and assess responses to anticancer drugs </plain></SENT>
</text></document>